摘要
Ⅲ期N2非小细胞肺癌(NSCLC)外科治疗5年生存率仅有15%左右。目前为止仍然没有术后辅助性化疗、放疗或化放疗能改善Ⅲ期N2NSCLC患者生存率的有力证据,新辅助化疗的的价值仍有争议。因此,可切除Ⅲ期NSCLC的治疗仍然以手术为主。
The5-year survival rate of patients with stageⅢ-N 2 non-small cell lung cancer(NSCLC)after surgical treatment was only15%.But there is no enough evidence that patients with stageⅢ-N 2 NSCLC should receive postoperative chemotherapy or radiotherapy.The argument of the value of neoadjuvant chemotherapy has not come to end.Surgery is still the major treatment for patients with stageⅢ-N 2 NSCLC.
出处
《肿瘤学杂志》
CAS
2004年第1期1-4,共4页
Journal of Chinese Oncology
关键词
治疗
癌
非小细胞肺
treatment
carcinoma,non-small cell lung
